Premium
High levels of circulating cell‐free DNA are a biomarker of active SLE
Author(s) -
Xu Yalan,
Song Yijun,
Chang Jiazhen,
Zhou Xiya,
Qi Qingwei,
Tian Xinping,
Li Mengtao,
Zeng Xiaofeng,
Xu Mengnan,
Zhang Wenjuan,
Cram David S,
Liu Juntao
Publication year - 2018
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.13015
Subject(s) - lupus nephritis , biomarker , medicine , immunology , antibody , cell free fetal dna , dna , serology , endocrinology , systemic lupus erythematosus , disease , chemistry , biology , pregnancy , fetus , biochemistry , prenatal diagnosis , genetics
Background High levels of circulating cell‐free DNA (cf DNA ) have been reported in patients with inflammatory conditions. The aim of the study was to investigate the levels of cf DNA in patients with systemic lupus erythematosus ( SLE ). Materials and methods Comparative groups comprised 22 nonpregnant and 36 pregnant women with SLE (test groups) and 60 nonpregnant and 199 pregnant women with no history of SLE (control groups). The levels of cf DNA in plasma were quantitated by a fluorometric ds DNA assay. Results Compared to controls, the median levels of cf DNA were significantly higher in nonpregnant SLE patients (7.38 ng/mL vs 4.6 ng/mL, P = 0.033) and in pregnant SLE patients (7.65 ng/mL vs 5.25 ng/mL, P = 0.003). Based on SLE disease activity index ( SLEDAI ) scores, the median cf DNA levels were significantly higher in patients with active disease (4 < SLEDAI < 15) compared with patients with inactive disease ( SLEDAI < 4) (13.58 ng/mL vs 6.72 ng/mL, P = 0.01). While there was a trend of increased cf DNA levels with higher SLEDAI scores ( R 2 = 0.3, P < 0.001), we found no association of increased cf DNA levels with nephritis, skin manifestations, multiorgan inflammations or with other inflammatory markers such as decreased C3 and C4 levels or increased anti‐ds DNA antibodies. Conclusions Our results suggest that in addition to classical SLE serological markers, measurement of circulating plasma cf DNA levels has potential as a useful biomarker for assessing SLE disease activity in patients and monitoring treatment.